Historical collection · First published Jul 17, 2025; added to EM Weekly Oct 27, 2026. This retrospective summary may be superseded by later evidence or guidance.
← All articlesIDSA 2025 Guideline Update on Complicated Urinary Tract Infections
Summary
IDSA suggests shorter treatment for improving cUTI: 5–7 days of an effective fluoroquinolone or 7 days of another effective antibiotic. It also supports IV-to-oral transition when patients improve, tolerate oral medication and have an active oral option. Duration starts on the first effective treatment day.
Why it matters
Use severity, prior cultures and resistance risks to choose empiric therapy, then narrow and reassess route and duration. Bacteremia alone does not require an entire IV course in a stable, source-controlled patient.
Study at a glance
- Design
- Guideline
- Population
- Adults with complicated UTI, including acute pyelonephritis and selected Gram-negative bacteremia.
- Sample size
- Not applicable
- Intervention
- Severity-informed antibiotic selection, oral transition and shorter duration.
- Comparator
- Longer courses or continued parenteral therapy.
- Primary endpoint
- Evidence-graded management recommendations.
Main findings
- Seven days is suggested for improving cUTI with Gram-negative bacteremia.
Limitations
Many supporting studies excluded severe sepsis, obstruction, abscess, catheters and immunocompromise. Suspected prostatitis and unresolved source-control problems need individualized treatment.
Recommendation strength
Short-course fluoroquinolone: conditional/moderate certainty; other antibiotics: conditional/very low. Oral switch: conditional/low; bacteremic switch: conditional/very low.
Read the primary source
Full text: Official society summary available.
Original sourceSource: https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/
Material reviewed: official society summary.
Source retrieved Oct 27, 2026. Historical backfill. Official IDSA recommendations and remarks reviewed; linked manuscript evidence tables and supplements were not reviewed. Official release July 17, 2025, rather than later journal issue dates. This is an original synopsis, not a reproduction.
Corrections & review history
No corrections recorded. Human review: not yet human-reviewed.